LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire-FirstCall/ --
- Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin Testing in U.S. Animal Models
An internationally renowned avian influenza expert today hailed "encouraging and exciting" results from experiments conducted by his research team. This study demonstrated impressive efficacy of a novel statin/caffeine combination, StatC(TM) in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse model.
To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/canopusbiopharma/34441/
Dr. Jiahai Lu, from the School of Public Health, Sun Yat-sen University in Guangzhou, China, has published extensively in the field of avian influenza, and has been researching the breakthrough compound StatC(TM) for the past two years on behalf of Canopus Biopharma (OTCPK:CBIA), a US corporation who discovered and patented the potential of this antiviral candidate.
"The global distribution of the highly pathogenic H5N1 avian influenza has caused the World Health Organization to show its profound concern regarding the possibility of the virus spreading from human to human in the future," stated Dr. Lu. "Furthermore, the development of resistance to two approved anti-influenza drugs, oseltamivir (Tamiflu(R)) and zanamivir (Relenza(R)), as well as the lack of adequate vaccines has increased the need of developing new antiviral drugs."
"Consequently, I am delighted to be involved in the preclinical research stage of this innovative antiviral candidate, and look forward to continuing our successful collaboration with Canopus Biopharma in this area."
Dr. Lu and his colleagues have conducted extensive animal studies with
StatC(TM) against three influenza strains, H5N1 (avian influenza, bird
flu), H1N1 (Spanish influenza) and H3N2 (Hong Kong influe
|SOURCE Canopus Biopharma INC|
Copyright©2008 PR Newswire.
All rights reserved